Abeona Therapeutics Inc. (ABEO) Stock

About Abeona Therapeutics Inc.

Abeona Therapeutics Inc. is led by CEO Vishwas Seshadri, employs 136 people, headquartered in US, publicly traded since 1980.

Abeona Therapeutics Inc. (ABEO) stock trades at $4.40 with a market capitalization of $251.61M. The stock is valued at a negative price-to-earnings (P/E) ratio of -4.43, reflecting a net loss over the last twelve months, price-to-book of 2.24, price-to-sales of 11.23. Over the past 52 weeks the stock has ranged between $4.00 and $7.65, and currently trades 42.5% below its 52-week high.

On profitability, Abeona Therapeutics Inc. generates a return on equity (ROE) of -41.69% (negative, reflecting a net loss), return on capital employed of -54.05%, an operating margin of -1483.33%, a net profit margin of -246.42%.

Abeona Therapeutics Inc. by the numbers, 2016–2025

Between 2016 and 2025 Abeona Therapeutics Inc. reported revenue of $1.0M rising to $6.0M, a change of +500.0% across 10 years. Compounded, revenue has grown -9.7% a year over five years, 81.7% over three, —% over the last twelve months. Net profit rose to $71.0M.

Operating margin went from -2686.3% in 2016 to -1536.9% in 2025, a gain of 1149.4 percentage points. The most recent net margin is -246.42%. On a trailing twelve-month basis to Jun '26, revenue is $25.0M and net profit $-62.0M.

Borrowings stand at $25.0M, cash from operations was $-76.0M in the latest year, positive in 0 of the last 10.

Return on equity has averaged -162.3% over five years, and was 44.6% in the most recent year.

The share price itself has compounded at —% a year over five years, —% over three, —% over the last year. Past price movement is history, not a forecast.

Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.

Abeona Therapeutics Inc. (ABEO) — frequently asked questions